Scholar Rock's ISEMBYLD Wins FDA Approval As First Muscle-Targeted Therapy For SMA

Scholar Rock's ISEMBYLD received FDA approval as the first muscle-targeted therapy for spinal muscular atrophy (SMA), marking a new treatment approach for this genetic disease.

This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 12 Sep 2026 and 14 Sep 2026.